Potentiation of cd95l-lnduced apoptosis of human malignant glioma cells by topotecan involves Inhibition of RNA Synthesis but not Changes in CD95 or CD95L Protein Expression1

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 3, 1998, Pages 1374-1382

  Winter, Stephan ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DACTINOMYCIN; FAS ANTIGEN; FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN BCL 2; PROTEIN P53; RNA; TOPOTECAN; DNA TOPOISOMERASE INHIBITOR; PROTEIN BAX; PROTEIN P21;

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GLIOMA; HUMAN; MOUSE; PATHOLOGY; ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL CYCLE G2 PHASE; CELL GROWTH; COMPLEX FORMATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SENSITIVITY; GLIOBLASTOMA; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DACTINOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FAS LIGAND PROTEIN; GLIOMA; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA; TOPOTECAN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032159285     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A and Stewart CF (1996) Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 37:195-202.
2. Beran M, Kantarjian H, O'Brien S, Koller C, Al-Bitar M, Arbuck S, Pierce S, Moore M, Abbruzzese JL, Andreef M, Keating M and Estey E (1996) Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88:2473-2479.
3. Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D and Poplack DG (1993a) Pédiatrie phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 53:1032-1036.
4. Blaney SM, Cole DE, Balis FM, Godwin K and Poplack DG (1993b) Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53:725-727.
5. Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, Allen JC, Sallan SE, Jakacki Rl, Lange BJ, Reaman GH, Horowitz ME, Poplack DG and Balis FM (1996) Phase II evaluation of topotecan for pédiatrie central nervous system tumors. Cancer 78:527-531.
6. Broom C (1996) Clinical studies of topotecan. Ann NY Acad Sei 803:264-271.
7. Danks MK, Garrett KE, Marion RC and Whipple DO (1996) Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res 56:1664-1673.
8. Dubrez L, Goldwasser F, Genne P, Pommier Y and Solary E (1995) The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leucémie cells to topoisomerase I and II inhibitors. Leukemia 9:1013-1024.
9. Fine HA, Dear KBG, Loeffler JS, Black PM and Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597.
10. Friedman, HS, Houghton PJ, Schold SC, Keir S and Bigner DD (1994) Activity of
11. 9-dimethylaminomethyl-10-hydroxycamptothecin against pédiatrie and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34:171-174.
12. Friesen C, Herr I, Krammer PH and Debatin KM (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 2:574-577.
13. Gobert C, Bracco L, Rossi F, Olivier M, Tazi J, Lavelle F, Larsen AK and Riou JF (1996) Modulation of DNA topoisomerase I activity by p53. Biochemistry 5:57785786.
14. Herben VMM, Ten Bokkel Huinink WW and Beijnen JH (1996) Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31:85-102.
15. Horwitz SB, Chang CK and Grollmann AP (1971) Studies on camptothecin: I. Effects on nucleic acid and protein synthesis. Mol Pharmacol 7:632-644.
16. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW and Houghton JA (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 34:229-239.
17. Jensen PB, Holm B, Sorensen M, Christensen IJ and Sehested M (1997) In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: Preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabine. Br J Cancer 75:869-877.
18. Kaufmann SH, Gore SD, Letendre L, Svingen PA, Kottke T, Buckwalter CA, Jones RJ, Grochow LB, Burke PJ, Donehower RC and Rowinsky EK (1996a) Factors affecting topotecan sensitivity in human leukemia samples. Ann NY Acad Sei 803:128-142.
19. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC and Rowinsky EK (1996b) Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88:734-741.
20. Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC and Rowinsky E (1997) Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood 89:2098-2104.
21. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, De Leon CG, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M and Kavanagh JJ (1996) Phase II study of intravenous topotecan as a 5-day infusion for refractory epitelial ovarian carcinoma. J Clin Oncol 14:1552-1557.
22. Lamond JP, Mehta MP and Boothman DA (1996) The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and irradiation. J Neuro-Oncol 30:1-6.
23. Lesser GJ and Grossmann S (1994) The chemotherapy of high-grade astrocytomas. Semin Oncol 21:220-235.
24. Li CJ, Averboukh L and Pardee AB (1993) -Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem 268:22463-22468.
25. Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawa C, Wainman N and Eisenhauer E, for the National Clinical Institute of Canada Clinical Trials Group (NCIC CTG.) (1996) Phase II study of topotecan in patients with recurrent malignant glioma. Ann Oncol 7:205-207.
26. Marchesini R, Colombo A, Caserini C, Perego P, Supino R, Capranico G, Tronconi M and Zunino F (1996) Interaction of ionizing radiation with topotecan in two human tumor cell lines. Int J Cancer 66:342-346.
27. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH and Galle PR (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99:403-413.
28. Nakatsu S, Kondo S, Kondo Y, Yin D, Peterson JW, Kaakaji R, Morimura T, Kikuchi H, Takeuchi J and Barnett GH (1997) Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 39:417-423.
29. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN and Hong WK (1996) Phase II study of topotecan in patients with advanced non-smallcell lung cancer previously untreated with chemotherapy. J Clin Oncol 14:503513.
30. Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR, Wilding G and Boothman DA (1995) -Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: A p53independent response. Cancer Res 55:3706-3711.
31. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH and Fontana A (1995) Loco-regional Fas/APO-1 (CD95) ligandmediated tumor cell killing in vivo Eur J Immunol 25:2253-2258.
32. Roth W, Fontana A, Trepel M, Dichgans J, Reed JC and Weller M (1997) Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 44:55-63.
33. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH and Donehower RC
34. (1992) Phase I and pharmacologie study of topotecan: A novel topoisomerase inhibitor. J Clin Oncol 10:647-656.
35. Schiller JH, Kirn KM, Hutson P, DeVore R, Glick J, Stewart J and Johnson D (1996) Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 14:2345-2352.
36. Seiter K, Feldman EJ, Halicka D, Traganos F, Darzynkiewicz Z, Lake D and Ahmed T (1997) Phase I clinical and laboratory evaluation of topotecan and cytarabin in patients with acute leukemia. J Clin Oncol 15:44-51.
37. Subramanian D, Kraut E, Staubus A, Young DC and Müller MT (1995) Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 55:2097-2103.
38. Sung C, Blaney SM, Cole DE, Baus FM and Dedrick RL (1994) A pharmakokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 54:5118-5122.
39. Traganos F, Seiter K, Feldman E, Halicka HD and Darzynkiewicz Z (1996) Induction of apoptosis by camptothecin and topotecan. Ann NYAcad Sei 803:101-110.
40. Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J and Weller M (1998) Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. J Neuro-OncoI.
41. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJS, Friedmann T, De Tribolet N and Cavenee WK (1994) Analysis of the p53 gene aid its expression in human glioblastoma cells. Cancer Res 54:649-652.
42. Wagenknecht B, Gulbins E, Lang F, Dichgans J and Weller M (1997) Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. FEES Lett 409:17-23.
43. Weingart JD, Thompson RC, Tyler B, Colvin OM and Brem H (1995) Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int J Cancer 62:605-609.
44. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y and Fontana A (1994a) Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells: Induction and modulation of sensitivity by cytokines. J Clin Invest 94:954-964.
45. 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Ear J Immunol 24:1293-1300.
46. Weller M and Fontana A (1995) The failure of current immunotherapy for malignant glioma: Tumor-derived TGF-β, T cell apoptosis, and the immune privilege of the brain. Brain Res Rev 21:128-151.
47. Weller M, Malipiero UV, Aguzzi A, Reed JC and Fontana A (1995a) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs ard therapeutic irradiation. J Clin Invest 95:2633-2643.
48. Weller M, Malipiero U, Rensing-Ehl A, Barr P and Fontana A (1995b) Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 55:2936-2944.
49. Weller M, Schmidt C, Roth W and Dichgans J (1997a) Chemotherapy of human malignant glioma: Prevention of efficacy by dexamethasone? Neurology 48:1704-1709.
50. Weller M, Trepel M, Grimmel C, Schabet M, Bremen D, Krajewski S and Reed J (1997b) Hypericin-induced apoptosis of human malignant glioma cells is ligh;dependent, independent of bcl-2 expression, and does not require wild-type p53. Neural Res 19:459-470.
51. Weller M, Weinstock C, Will C, Wagenknecht B, Dichgans J, Lang F and Gulbins 3 (1997c) CD95-dependent T cell killing by glioma cells expressing CD95 ligand: More on tumor immune escape, the CD95 counterattack, and the immune priv lege of the brain. Cell Physiol Biochem 7:282-288.
52. Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J and Groscurth P (1997d) Topoisomerase I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and -lapachone. Int J Cancer 73:707-714.
53. Weller M, Kleihues P, Dichgans J and Ohgaki H (1998) CD95 ligand: Lethal weapon for malignant glioma? Brain Pathol.
54. cdc2kinase. Nat Med 2:1140-1143.
55. Yonehara S, Ishii A and Yonehara M (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169:1747-1756.
56. Send reprint requests to: Dr. Michael Weller, Neurologische Klinik der Universität Tübingen, Hoppe-Seyler-Strasse 3, D-72076 Tübingen, Germany E-mail: michael.weller@uni-tuebingen.de